Navigation Links
PTC Therapeutics Announces Data Supporting Cough Frequency as a New Outcome Measure in Evaluating Treatments for Cystic Fibrosis
Date:5/21/2008

velopment efforts would benefit from reliable quantitative endpoints that are clinically meaningful because they directly measure changes in how a patient feels and functions.

"The ability to quantify cough represents a significant step forward in our understanding of one of the most prominent symptoms of CF," added Preston Campbell, III, M.D., Executive Vice President of Medical Affairs at the Cystic Fibrosis Foundation. "A significant reduction in cough frequency would be of real value to patients."

The study was designed to assess cough frequency as a measure of clinical benefit. Quantitative measurement was achieved using a new technology, the VivoMetrics(R) LifeShirt(R), which integrates cough signals from chest wall motion transducers and a throat microphone and stores the data for computer analysis. FEV1 (Forced Expiratory Volume in the first second) and FVC (forced vital capacity) -- key measures of lung function -- were assessed by spirometry, and patients completed a symptom survey.

Patients included 19 adults not in CF exacerbation. Although there was occasional neck pressure due to the throat microphone, compliance was excellent, with cough data collected for a median of 24 hours. Cough frequency averaged 643 coughs per day (ranging from 324 to 1,569 coughs per day) and tended to increase with lower FEV1 and greater age.

"Anecdotal information concerning cough frequency in CF patients led us to assess cough quantitatively using the LifeShirt(R)," said Langdon Miller, M.D., Chief Medical Officer of PTC. "The cough frequency data announced today highlights the potential for cough assessment as an outcome measure that may be used in the development of new therapies for CF. We look forward to presenting data on the effect of PTC124 on cough frequency at the 31st annual European Cystic Fibrosis Society Conference in June, and to initiating longer-term trials later this year to further evaluate the clinical efficacy of PTC124 in pat
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease
2. PacificGMP Completes GMP Product Fill for Trius Therapeutics
3. Velcura Therapeutics, Inc. Reports Successful Phase 1 Clinical Trial of Novel Bone Disease Therapy
4. Vicus Therapeutics Records Last Patient Visit of Phase 2, VT-122 Trial for the Treatment of Cachexia in Patients With Advanced Lung Cancer
5. Cara Therapeutics Initiates Phase 1 Clinical Trial of Novel Analgesic, CR845
6. PTC Therapeutics Announces Initiation of Phase 2b Registration-Directed Clinical Trial of PTC124 in Duchenne/Becker Muscular Dystrophy
7. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
8. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
9. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
10. Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System
11. Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)...  Ameritox, the nation,s leader in pain medication ... to become part of its Urine Drug Monitoring ... and improve the clinical outcomes for injured workers. ... manager in the workers, compensation industry, has used ... management strategy for several years. By establishing a ...
(Date:5/23/2013)... 2013  BioElectronics Corporation (OTC Pink: BIEL), the maker ... the FDA panel meeting for non-thermal shortwave diathermy: ... Shortwave Therapy Meeting was held on May 21, 2013 ... focus of the meeting was very narrow, in that ... on the application of non-thermal shortwave diathermy for the ...
(Date:5/23/2013)... , May 23, 2013  CAS Medical Systems, Inc. (NASDAQ: ... for non-invasive patient monitoring, today announced that Thomas ... present at the 2 nd Annual Marcum MicroCap Conference ... in New York City . ... in the Estate 10 room and will be available via ...
Breaking Medicine Technology:Ameritox Joins with Progressive Medical in Urine Drug Monitoring Network to Help Improve Care of Injured Workers 2Ameritox Joins with Progressive Medical in Urine Drug Monitoring Network to Help Improve Care of Injured Workers 3BioElectronics and Pulsed Shortwave Therapy Make Progress 2CASMED to Present at the 2nd Annual Marcum MicroCap Conference 2
(Date:5/23/2013)... May 23, 2013 Dr. Damon Huffman of ... suffer from gum disease a revolutionary new treatment method with ... millions of Americans who suffer from periodontal disease, and many ... treatment. Dr. Huffman is hoping that LANAP will encourage ... treatment. , Periodontal disease can cause gums ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Da Vinci ... in a trial in Washington State May 23, according ... clients in surgical robot lawsuits , expresses disappointment ... da Vinci lawsuits to not read a single verdict ... case (Estate of Fred E. Taylor v. Intuitive Surgical ...
(Date:5/23/2013)... 2013 Memorial Day Focus Spotlight on ... been a part of the U.S. Military for more ... preceding it, these men and women will be honored ... of America. As veterans transition to civilian life, ... the workplace chaplaincy world. , Marketplace Chaplains, America’s ...
(Date:5/23/2013)... Live Lead Pros , with ... best business lead solution via its smart solution ... solution features Free Web Based Account Management, Database ... and "Automatic Transfer Retry". The company has recently ... management system. , Its Free Database Usage offers ...
(Date:5/23/2013)... 23, 2013 The Rottenstein Law Group ... has created the Tylenol Lawsuit Information Center at ... users and those who are considering filing lawsuits. ... potentially cause severe liver damage, according to a 2009 ... In the “safety communication,” the FDA warned consumers against ...
Breaking Medicine News(10 mins):Health News:Humble, TX Dentist, Dr. Damon Huffman Now Offers Laser Periodontal Disease Treatment to Gum Disease Patients 2Health News:Da Vinci Surgical Robot Lawsuit News: Rottenstein Law Group LLP Comments on Intuitive Win in Negligent Training Trial 2Health News:Memorial Day Focus Spotlight on Military Chaplains Transitioning in the Marketplace 2Health News:Memorial Day Focus Spotlight on Military Chaplains Transitioning in the Marketplace 3Health News:Live Lead Pros Announces The Benefits of Comprehensive Campaign Delivery and Management System 2Health News:Rottenstein Law Group LLP Now Accepting Tylenol Cases, Announces New Tylenol Lawsuit Information Center 2
... 26, 2008 Adding noninvasive imaging to current risk-assessment ... of developing heart disease, UT Southwestern Medical Center researchers ... Southwestern-led Dallas Heart Study to determine whether using computed ... and blockages could identify more people at high risk ...
... Desso ... Turf, BRUSSELS, Belgium, May ... a few synthetic turf,fields. The fields in question are not manufactured by Desso ... that,their pitch doesn,t contain any lead., All Desso synthetic turf products and ...
... the clumps of mutant protein that drive neurodegeneration in ... make an intracellular antibody or "intrabody" against huntingtin, the ... people with Huntington,s. , Injecting the virus into the ... ability to move their limbs, although it does not ...
... mapmaker and a mathematician may seem like an unlikely duo, ... and kept millions of sailors from getting lost at ... at Rockefeller University, is making history of their own. By ... they have become the first to see, in real time ...
... Corporate Seminars Caught In Crossfire, SAN FRANCISCO, ... is not a party to a lawsuit that ... international training and,development company is inappropriately referenced in ... suit, filed by Scott Glasgow, is claiming sexual,harassment ...
... First we knew, then we didn,t. A factor, ... egg is crucial for promoting the oscillations in free ... activation processes. Phospholipase C zeta (PLCZ1) is a strong ... the zygotes pronuclei where its ability to promote calcium ...
Cached Medicine News:Health News:Increased screening may better predict those at higher risk for heart disease, researchers report 2Health News:It's Safe to Play on Desso Synthetic Turf 2Health News:It's Safe to Play on Desso Synthetic Turf 3Health News:'Intrabody' can mop up mutant protein in Huntington's disease model 2Health News:Scientists image a single HIV particle being born 2Health News:Scientists image a single HIV particle being born 3Health News:International Training and Development Company, Landmark Education, Mischaracterized as Religion 2Health News:June 2008 highlights 2
... Vision5L Digital Holter ... or 7-lead, 3-channel,Holter ... signal preview,screen. Fast ... a compact,flash card ...
... The CSV-1000CVA20/30 test face provides three contrast levels ... from 20/16 to 20/100. This test is designed ... as associated with contact lens evaluation or due ... the test provide the same contrast and acuity ...
The CSV-1000SLanC test face provides the same tests as the standard CSV-1000S, except that the acuity test is presented in Landolt C format. , ,This test is very useful when testing patients who cann...
Contrast sensitivity testing, glare sensitivity testing and ETDRS acuity testing are provided in the self standardized CSV-1000 instrument. Patented photocell circuitry automatically monitors and cal...
Medicine Products: